Logo

Sangamo Therapeutics

Sangamo, Genentech Ink Deal to Advance Genomic Medicines for Alzheimer's, Other Neurological Diseases

Sangamo exclusively licensed certain technology to Genentech, which it will use to develop tau-directed medicines.

Pfizer to Discuss Positive Phase III Hemophilia A Gene Therapy Results With Regulators

Patients who received Pfizer and Sangamo Therapeutics' giroctocogene fitelparvovec experienced improvements in total annualized bleeding rate.

Sangamo Prices $24M Direct Offering of Common Stock

The firm will use the proceeds for general corporate purposes and to advance its pipeline of neurology-focused genomic medicines.

Sangamo Therapeutics Gets FDA Feedback on BLA for Fabry Disease Gene Therapy

Although the regulatory path for isaralgagene civaparvovec is becoming clearer, the firm won't advance a registrational trial without a commercialization partner.

Sangamo Therapeutics Discussing Phase III Fabry Disease Trial With FDA as It Seeks Program Support

The firm has said it is pausing investment into the gene therapy program until it secures a partnership or financing.